Flutiform
Sponsors
Mundipharma Research Limited
Conditions
AsthmaAsthma BronchialeChronic Obstructive Pulmonary Disease
Phase 3
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
CompletedNCT00563056
Start: 2007-09-30End: 2008-04-30Updated: 2018-10-24
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma
CompletedNCT01099722
Start: 2010-04-30End: 2011-07-31Updated: 2018-10-24
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
CompletedNCT01511367
Start: 2012-03-31End: 2013-11-30Target: 498Updated: 2018-10-24
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
CompletedNCT01946620
Start: 2013-10-31End: 2016-05-31Updated: 2018-10-24